Clinical Trials

Brief Overview:

Patients who have been diagnosed with glioblastoma multiforme and whose tumors have progressed after radiation therapy may be eligible. Patients would undergo surgical removal of the recurrent tumor and would then have a gel infused with Taxol chemotherapy injected into the surgical cavity.
Inclusion Criteria
- At least 18 to less than 70 years of age
- Must have received prior conventional radiation therapy completed >4 weeks prior to enrollment
- Good neurologic performance status

Exclusion Criteria
- Received any type of sterotactic radiosurgery or brachytherapy with the exception of a sterotactic radiosurgery boost as part of the initial radiation therapy
- History of seizures refractory to two or more anticonvulsant medications
- Receipt of any cytotoxic chemotherapeutic agent within 28 days of Study Day 1 (or if nitrosourea within 6 weeks of Study Day 1)
- Received any intracerebral investigational agent
- Receipt of another investigational drug or device within 28 days of the planned surgery